Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Upper tract urothelial carcinoma

  • HEOR and market access activities in upper tract urothelial carcinoma (UTUC)
  • Strategic consultancy for market access support in UTUC
  • Updates to a Health Impact Projection (HIP) model in locally advanced or metastatic urothelial cancer
  • Health economic data analysis in low-grade urothelial cancer

Uterine fibroids

  • Consultation on the development of a diary to assess uterine fibroids
  • Assessment of a minimal clinically important difference in a uterine fibroid symptom and quality of life questionnaire
  • Design and pilot testing of an ePRO in uterine fibroids
  • Regulatory and statistical support for an FDA claim in women with uterine fibroids
  • Development of disease-specific modules for fibroids


  • Review of evidence requirements in uveitis for national and local reimbursement submissions in five European countries, with reviews of local language guidance
  • Strategic consultancy meeting on uveitis
  • Core value dossier in uveitis
  • Core value dossier in paediatric uveitis
  • Core value dossier for a treatment in uveitis
  • Update of a core value dossier in uveitis
  • Development of a HEOR strategy for uveitis

Value dossiers

We have a vast amount of experience in this area including the creation of global/core value dossiers, AMCP dossiers, payer value/evidence dossiers and reimbursement dossiers.

  • Actinic keratosis
  • Anaesthesia
  • Ankylosing spondylitis
  • Aortic stenosis
  • Asthma
  • Atopic dermatitis
  • Attention deficit hyperactivity disorder (ADHD)
  • Breast cancer
  • Chronic obstructive pulmonary disease (COPD)
  • Colonoscopy
  • Crohn’s disease
  • Dengue fever
  • Diabetes
  • Fabry disease
  • Febrile neutropenia
  • Fungal infections
  • Gastric cancer
  • Glaucoma
  • Glioblastoma
  • Gram negative infections
  • Heart failure
  • Heroin addiction
  • Hidradenitis suppurativa
  • Human papilloma virus (HPV)
  • Infertility
  • Inflammatory bowel disease
  • Influenza
  • Insomnia
  • Kidney disease/kidney failure
  • Leukaemia
  • Liver transplant
  • Lung cancer (small cell and non-small cell)
  • Melanoma
  • Multiple myeloma
  • Multiple sclerosis (MS)
  • Myelodysplastic syndrome
  • Myelofibrosis
  • Nutritional supplements
  • Osteoarthritis
  • Pain (acute pain, chronic pain and trauma pain)
  • Pancreatic cancer
  • Parkinson’s disease
  • Phenylketonuria
  • Prostate cancer
  • Psoriasis
  • Psoriatic arthritis
  • Refractory ascites
  • Respiratory syncytial virus
  • Restless leg syndrome
  • Rheumatoid arthritis
  • Schizophrenia
  • Stress urinary incontinence
  • Surgery
  • Uveitis
  • Varicella


  • Update to payer value slide deck for varicella
  • Payer value deck for a varicella vaccine
  • Payer material development for vaccines in varicella
  • Response to payer questions deck in varicella
  • e-v@luate platform on vaccines for varicella
  • Value communication deck in varicella


  • Communication of the economic burden of vertigo based on the REVERT registry
  • Manuscript on clinical outcomes in vertigo

Von Willebrand disease

  • Development and validation of a PRO measure in von Willebrand disease and haematology
  • Pre-validation work to inform a clinical trial in von Willebrand disease
  • In-trial validation of a PRO instrument in von Willebrand disease


  • Development of a paediatric, adolescent and adult QoL measure of viral warts
  • ClinRO development for common warts
  • Development, evaluation, and regulatory support for the Physician Wart Assessment

Weight loss, weight gain, eating disorders, obesity and nutrition

  • Update of a budget impact model for an anorectic anti-obesity drug for cardiometabolic risk
  • Service impact model on cardiovascular complications in obesity
  • Value evidence story in obesity
  • Adaptation of a budget impact model on an anorectic anti-obesity drug for Latin America
  • Strategic guidance to support price and reimbursement in the EU in obesity
  • Gap analysis of three PRO questionnaires for obesity trials
  • Development of an instrument to assess subject perception of two gastric bands in obesity
  • Focus groups for the development of a treatment expectations questionnaire and the face and content validition of a visual analogue scale (VAS) for patients with obesity
  • PRO strategy in obesity
  • Development and validation of an adherence to diet questionnaire in obesity
  • Translation of an adherence to diet questionnaire in obesity
  • Outcomes consulting for a treatment in obesity
  • Item reduction for a questionnaire in obesity
  • Value evidence story in obesity
  • Development of a PRO measure in binge eating disorder
  • Abstract and poster on binge eating disorder
  • Global value dossier on an oral nutritional supplement
  • Position paper on an adherence questionnaire in weight loss
  • Psychometric validation of a cohort study on adherence to lifestyle changes in weight loss and smoking cessation
  • Development and validation of a questionnaire to assess well-being changes in people who would like to lose weight and quit smoking
  • Manuscript on the development and validation of a lifestyle changes questionnaire for weight loss
  • Statistical analysis and dossier development for localized fat reduction and body contouring
  • Cognitive interviews for PRO instruments in localized fat reduction and body contouring
  • Development of a PRO questionnaire in abdominoplasty (tummy tuck)

Wound care

  • Analysis of client’s value research in wound care treatment
  • Investigation of ‘Trauma’ for a treatment in wound care
  • e-v@luate platform for wound care evidence
  • Value demonstration on a new wound care technology and the cost of pain management, allowing data to be tailored for local markets and local payers
  • Review of a Japanese pricing submission in wound care
  • Development and validation of a ClinRO to measure changes in peristomal skin

X-linked hypophosphatemia (XLH)

  • Development of an FDA dossier in X-Linked Hypophosphatemia (XLH)
  • Validation activities of an FDA dossier in XLH
  • Psychometric validation of the Brief Pain Inventory (BPI) and Western Ontario and McMaster osteoarthritis index (WOMAC) in XLH using online survey data
  • Exploration of content validity of PROMIS items for use in children with XLH
  • Psychometric evaluation of the BPI-SF and WOMAC in XLH using phase III trial data

Yellow fever

  • Burden of disease literature review on yellow fever in the UK and Ireland